1,25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density

Margherita Teresa-Anna Cantorna, Debra A. Hullett, Claudio Redaelli, Curtis R. Brandt, Jean Humpal-Winter, Hans W. Sollinger, Hector F. Deluca

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background. Recently, we have shown that 1,25-dihydroxyvitamin D3 prolongs graft survival in mice and rats when the donor and recipient differ at two or more major histocompatability loci. Among the most serious side effects encountered with the currently available transplantation antirejection drugs are an increased susceptibility to infection and decreased bone mineralization. Our results suggest that 1,25-dihydroxyvitamin D3 prolongs graft survival without these side effects of bone loss and susceptibility to infection. Methods. We compared the ability of 1,25- dihydroxyvitamin D3-treated, nontreated, or cyclosporine (CsA)-treated mice to resist infection with Candida albicans and herpes simplex virus-1. To determine bone density, femurs were collected from nontreated, 1-25- dihydroxyvitamin D3-treated (50 ng/mouse/day), or CsA-treated (25 mg/kg/day) mice, and bone ash was determined. Results. Here we show that 1,25- dihydroxyvitamin D3 treatment does not increase the susceptibility of the host to fungal or viral infection. Furthermore, CsA causes bone loss, whereas 1,25-dihydroxyvitamin D3 actually increases bone mass. Conclusions. The use of 1,25-dihydroxyvitamin D3 and its analogs to increase transplant survival will avoid bone loss and opportunistic infection, two important disadvantages of the most widely used transplant antirejection drugs-CsA and the glucocorticoids.

Original languageEnglish (US)
Pages (from-to)828-831
Number of pages4
JournalTransplantation
Volume66
Issue number7
DOIs
StatePublished - Oct 15 1998

Fingerprint

Calcitriol
Graft Survival
Bone Density
Infection
Bone and Bones
Transplants
Physiologic Calcification
Mycoses
Opportunistic Infections
Human Herpesvirus 1
Virus Diseases
Candida albicans
Pharmaceutical Preparations
Femur
Cyclosporine
Glucocorticoids
Transplantation

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Cantorna, Margherita Teresa-Anna ; Hullett, Debra A. ; Redaelli, Claudio ; Brandt, Curtis R. ; Humpal-Winter, Jean ; Sollinger, Hans W. ; Deluca, Hector F. / 1,25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. In: Transplantation. 1998 ; Vol. 66, No. 7. pp. 828-831.
@article{ed5091552b5e402396c4e26af8ecc444,
title = "1,25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density",
abstract = "Background. Recently, we have shown that 1,25-dihydroxyvitamin D3 prolongs graft survival in mice and rats when the donor and recipient differ at two or more major histocompatability loci. Among the most serious side effects encountered with the currently available transplantation antirejection drugs are an increased susceptibility to infection and decreased bone mineralization. Our results suggest that 1,25-dihydroxyvitamin D3 prolongs graft survival without these side effects of bone loss and susceptibility to infection. Methods. We compared the ability of 1,25- dihydroxyvitamin D3-treated, nontreated, or cyclosporine (CsA)-treated mice to resist infection with Candida albicans and herpes simplex virus-1. To determine bone density, femurs were collected from nontreated, 1-25- dihydroxyvitamin D3-treated (50 ng/mouse/day), or CsA-treated (25 mg/kg/day) mice, and bone ash was determined. Results. Here we show that 1,25- dihydroxyvitamin D3 treatment does not increase the susceptibility of the host to fungal or viral infection. Furthermore, CsA causes bone loss, whereas 1,25-dihydroxyvitamin D3 actually increases bone mass. Conclusions. The use of 1,25-dihydroxyvitamin D3 and its analogs to increase transplant survival will avoid bone loss and opportunistic infection, two important disadvantages of the most widely used transplant antirejection drugs-CsA and the glucocorticoids.",
author = "Cantorna, {Margherita Teresa-Anna} and Hullett, {Debra A.} and Claudio Redaelli and Brandt, {Curtis R.} and Jean Humpal-Winter and Sollinger, {Hans W.} and Deluca, {Hector F.}",
year = "1998",
month = "10",
day = "15",
doi = "10.1097/00007890-199810150-00003",
language = "English (US)",
volume = "66",
pages = "828--831",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

1,25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. / Cantorna, Margherita Teresa-Anna; Hullett, Debra A.; Redaelli, Claudio; Brandt, Curtis R.; Humpal-Winter, Jean; Sollinger, Hans W.; Deluca, Hector F.

In: Transplantation, Vol. 66, No. 7, 15.10.1998, p. 828-831.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 1,25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density

AU - Cantorna, Margherita Teresa-Anna

AU - Hullett, Debra A.

AU - Redaelli, Claudio

AU - Brandt, Curtis R.

AU - Humpal-Winter, Jean

AU - Sollinger, Hans W.

AU - Deluca, Hector F.

PY - 1998/10/15

Y1 - 1998/10/15

N2 - Background. Recently, we have shown that 1,25-dihydroxyvitamin D3 prolongs graft survival in mice and rats when the donor and recipient differ at two or more major histocompatability loci. Among the most serious side effects encountered with the currently available transplantation antirejection drugs are an increased susceptibility to infection and decreased bone mineralization. Our results suggest that 1,25-dihydroxyvitamin D3 prolongs graft survival without these side effects of bone loss and susceptibility to infection. Methods. We compared the ability of 1,25- dihydroxyvitamin D3-treated, nontreated, or cyclosporine (CsA)-treated mice to resist infection with Candida albicans and herpes simplex virus-1. To determine bone density, femurs were collected from nontreated, 1-25- dihydroxyvitamin D3-treated (50 ng/mouse/day), or CsA-treated (25 mg/kg/day) mice, and bone ash was determined. Results. Here we show that 1,25- dihydroxyvitamin D3 treatment does not increase the susceptibility of the host to fungal or viral infection. Furthermore, CsA causes bone loss, whereas 1,25-dihydroxyvitamin D3 actually increases bone mass. Conclusions. The use of 1,25-dihydroxyvitamin D3 and its analogs to increase transplant survival will avoid bone loss and opportunistic infection, two important disadvantages of the most widely used transplant antirejection drugs-CsA and the glucocorticoids.

AB - Background. Recently, we have shown that 1,25-dihydroxyvitamin D3 prolongs graft survival in mice and rats when the donor and recipient differ at two or more major histocompatability loci. Among the most serious side effects encountered with the currently available transplantation antirejection drugs are an increased susceptibility to infection and decreased bone mineralization. Our results suggest that 1,25-dihydroxyvitamin D3 prolongs graft survival without these side effects of bone loss and susceptibility to infection. Methods. We compared the ability of 1,25- dihydroxyvitamin D3-treated, nontreated, or cyclosporine (CsA)-treated mice to resist infection with Candida albicans and herpes simplex virus-1. To determine bone density, femurs were collected from nontreated, 1-25- dihydroxyvitamin D3-treated (50 ng/mouse/day), or CsA-treated (25 mg/kg/day) mice, and bone ash was determined. Results. Here we show that 1,25- dihydroxyvitamin D3 treatment does not increase the susceptibility of the host to fungal or viral infection. Furthermore, CsA causes bone loss, whereas 1,25-dihydroxyvitamin D3 actually increases bone mass. Conclusions. The use of 1,25-dihydroxyvitamin D3 and its analogs to increase transplant survival will avoid bone loss and opportunistic infection, two important disadvantages of the most widely used transplant antirejection drugs-CsA and the glucocorticoids.

UR - http://www.scopus.com/inward/record.url?scp=0032532198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032532198&partnerID=8YFLogxK

U2 - 10.1097/00007890-199810150-00003

DO - 10.1097/00007890-199810150-00003

M3 - Article

VL - 66

SP - 828

EP - 831

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 7

ER -